Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin-Reference-Cited by-同舟云学术

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

Published:2015-07-17 Issue:2 Volume:34 Page:157-162
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

van de Putte Elisabeth E. Fransen,Mertens Laura S.,Meijer Richard P.,van der Heijden Michiel S.,Bex Axel,van der Poel Henk G.,Kerst J. Martijn,Bergman Andries M.,Horenblas Simon,van Rhijn Bas W. G.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-015-1636-y.pdf

Reference22 articles.

1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 48:202–206

2. Sherif A, Holmberg L, Rintala E et al (2004) Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 45:297–303

3. International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, the Australian Bladder Cancer Study Group, et al. (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 Trial. J Clin Oncol 29:2171–7

4. Fedeli U, Fedewa SA, Ward EM (2011) Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003–2007. J Urol 185:72–78

5. David KA, Milowsky MI, Ritchey J et al (2007) Low incidence of perioperative chemotherapy for stage III bladder cancer 1998–2003: a report from the National Cancer Data Base. J Urol 178:451–454

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen;Urology;2024-06

2. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study;The Lancet Oncology;2024-02

3. Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis;BMC Cancer;2023-11-06

4. Phase II study of neoadjuvant chemotherapy with four cycles of dose‐dense MVAC followed by radical cystectomy in Korean patients with muscle‐invasive or locally advanced urothelial carcinoma of bladder;Asia-Pacific Journal of Clinical Oncology;2023-07-17

5. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer;Current Treatment Options in Oncology;2023-07-10